Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: acquaintances (2), links (874), friends (308), contacts (1000)

NIHR BRC Theme ACDL

Description: NIHR BRC Theme Academic Career Development Lead Call for Expressions of Interest The University Hospital Southampton NHS Foundation Trust (UHS) and
Url: /Media/Southampton-Clinical-Research/Downloads/NIHR-BRC-Theme-ACDL.docx

NIHR BRC Theme Academic Career development Leads

Description: NIHR BRC Theme Academic Career Development Lead Call for Expressions of Interest The University Hospital Southampton NHS Foundation Trust (UHS) and
Url: /Media/Southampton-Clinical-Research/Downloads/NIHR-BRC-Theme-Academic-Career-development-Leads.pdf

Echogenic bowel-3503-PIL

Description: A baby is said to have an echogenic bowel when their bowel appears 'brighter' than usual on an ultrasound scan. It
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Echogenic-bowel-3503-PIL.pdf

Tisacel - Cyclophosphamide (500) - Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY ALL – TISACEL– CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) Regimen This regimen will only
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Tisacel-Cyclophosphamide-500-Fludarabine-30-Ver1.pdf

Brexucel - Cyclophosphamide (900) - Fludarabine (25)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY ALL – BREXUCEL – CYCLOPHOSPHAMIDE (900) – FLUDARABINE (25) This regimen will only be
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Brexucel-Cyclophosphamide-900-Fludarabine-25.pdf

Tisacel -Cyclophosphamide (250)-Fludarabine (25)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY DLBCL/ FL – TISACEL – FLUDARABINE (25) – CYCLOPHOSPHAMIDE (250) Regimen This regimen will
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Tisacel-Cyclophosphamide-250-Fludarabine-25.pdf

Brexucel - Cyclophosphamide (500) - Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY MCL – BREXUCEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) This regimen will only be
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Brexucel-Cyclophosphamide-500-Fludarabine-30.pdf

Axicel-Cyclophosphamide(500)-Fludarabine(30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY AXICEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) This regimen will only be available
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Axicel-Cyclophosphamide500-Fludarabine30.pdf

Avelumab(800mg)

Description: Chemotherapy Protocol BLADDER CANCER AVELUMAB (800mg) Regimen  Bladder Cancer - Avelumab Indication  Avelumab is indicated as monotherapy for the first-line maintenance
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Avelumab800mg.pdf

Nivolumab ver 1 (NSCLC)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab This regimen may require funding. Regimen NSCLC – Nivolumab Indication Metastatic squamous non
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-ver-1.pdf

101 to 110 of 647

Previous … 9 10 11 12 13 … Next